Tildrakizumab

• CAT Number: I042447
• CAS Number: 1326244-10-3
• Molecular Weight: 144.4 (kDa)
• Purity: ≥95%

Tildrakizumab (Cat No.: I042447) is a humanized IgG1/k monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By inhibiting IL-23 signaling, Tildrakizumab reduces the activation of Th17 cells and the production of pro-inflammatory cytokines, making it effective in treating chronic inflammatory conditions such as moderate-to-severe plaque psoriasis. It is administered via subcutaneous injection and provides long-lasting symptom relief. Tildrakizumab is also being studied for its potential in other autoimmune and inflammatory diseases.

Reference

[1]. Papp K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.
[Content Brief]

[2]. Zhou L, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021 Jan-Dec;13(1):1964420.
[Content Brief]

[3]. Santostefano M, et al. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates. Regul Toxicol Pharmacol. 2019 Nov;108:104476.
[Content Brief]